Home
Categories
EXPLORE
True Crime
Comedy
Business
Society & Culture
Health & Fitness
Sports
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Podjoint Logo
US
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/c6/c6/b5/c6c6b556-e872-0073-99bc-203a58c6c34d/mza_4988842973696844236.jpg/600x600bb.jpg
Evolving Minds By Pink Elephant
Pink Elephant Team
3 episodes
1 week ago
Go beyond the FDA approval headlines and into the REAL business of psychedelic medicine. While most eyes are on the drug developers, venture capitalist Maria Velkova shares where the smart money is going. The Tabula Rasa Ventures managing partner tells the untold story of the critical infrastructure needed for psychedelics to succeed post-approval, Big Pharma’s recent entry into the space, the maturation of the industry beyond the hype, and the massive commercial hurdles that many are overloo...
Show more...
Entrepreneurship
Business
RSS
All content for Evolving Minds By Pink Elephant is the property of Pink Elephant Team and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Go beyond the FDA approval headlines and into the REAL business of psychedelic medicine. While most eyes are on the drug developers, venture capitalist Maria Velkova shares where the smart money is going. The Tabula Rasa Ventures managing partner tells the untold story of the critical infrastructure needed for psychedelics to succeed post-approval, Big Pharma’s recent entry into the space, the maturation of the industry beyond the hype, and the massive commercial hurdles that many are overloo...
Show more...
Entrepreneurship
Business
Episodes (3/3)
Evolving Minds By Pink Elephant
Where is the REAL Money in Psychedelics? | Opportunities and Hurdles After FDA Approval
Go beyond the FDA approval headlines and into the REAL business of psychedelic medicine. While most eyes are on the drug developers, venture capitalist Maria Velkova shares where the smart money is going. The Tabula Rasa Ventures managing partner tells the untold story of the critical infrastructure needed for psychedelics to succeed post-approval, Big Pharma’s recent entry into the space, the maturation of the industry beyond the hype, and the massive commercial hurdles that many are overloo...
Show more...
1 month ago
45 minutes

Evolving Minds By Pink Elephant
The Psychedelic Gold Rush Is Over? Big Pharma, AI, and Psychedelic Research Inside the NHS
Go inside the REAL business of psychedelic medicine. While everyone talks about investment and FDA headlines, George McBride is on the front lines doing the essential work. The Clerkenwell Health co-founder reveals the untold story of navigating psychedelic clinical trials, Big Pharma’s growing interest, public-private partnerships with the NHS, the future of AI in psychedelic clinical trials, and much more. A candid and insightful look at innovation, regulation, and what it really takes to b...
Show more...
2 months ago
50 minutes

Evolving Minds By Pink Elephant
Why Psychedelic Startups Hit a Wall? Ronan Levy on Field Trip’s Rise, Ketamine Clinics & What’s Next
Today’s guest is Ronan Levy, co-founder and former CEO of Field Trip Health, joins Jason Najum to reflect on the explosive rise and collapse of one of the first public psychedelic therapy companies. #PsychedelicStartups #KetamineClinics #mentalhealthinnovation #mentalhealthpodcast In this raw and insightful conversation, Ronan shares: - How Field Trip raised $100M and listed on the NASDAQ - Why psychedelic therapy clinics are hard to scale - What went wrong with the ketamine cl...
Show more...
3 months ago
49 minutes

Evolving Minds By Pink Elephant
Go beyond the FDA approval headlines and into the REAL business of psychedelic medicine. While most eyes are on the drug developers, venture capitalist Maria Velkova shares where the smart money is going. The Tabula Rasa Ventures managing partner tells the untold story of the critical infrastructure needed for psychedelics to succeed post-approval, Big Pharma’s recent entry into the space, the maturation of the industry beyond the hype, and the massive commercial hurdles that many are overloo...